To present findings from Science Advances (June 2026) on systematic female underrepresentation in biomedical research and the epidemiological consequences for treatment efficacy estimates.

Systematic analysis of sex representation in published biomedical research from 1980-2026. Examination of NIH clinical trial data showing sex enrollment ratios. Analysis of treatment efficacy differences in sex-disaggregated outcome data. Review of journal editorial policies and compliance rates.

Research published in Science Advances (June 2026) documents what researchers term "precision medicine's blind spot": for decades, biomedical research systematically excluded female participants — both human and animal — from clinical trials and preclinical studies, creating a knowledge gap that affects treatment efficacy across multiple disease domains.

The core finding: Researchers historically excluded female subjects, particularly in animal studies, citing the "perceived complexity" of hormonal cycles. This led to a systematically male-biased evidence base for drug efficacy, dosing, and side effect profiles. When these treatments were later scaled to predominantly female populations, efficacy often differed significantly from published trial results.

Documented consequences: 1. Cardiovascular disease: Women's presentation of myocardial infarction differs substantially from men's, yet clinical trial protocols optimized for male-typical presentation led to systematic under-diagnosis and delayed treatment in female patients.

Sex-disaggregated analysis of historical trials showed that commonly prescribed dosages were suboptimal for women due to pharmacokinetic differences. 2. Neurological conditions: Autoimmune neurological diseases (MS, myasthenia gravis, autoimmune encephalitis) have higher prevalence and severity in women but were historically studied in predominantly male cohorts.

Sex-specific immune response differences mean treatment protocols derived from male-majority trials underperform in female populations. 3. Pain management: Opioid response, tolerance, and side effect profiles differ substantially between sexes due to receptor distribution and pharmacokinetic sex differences.

Yet pain management trials historically used predominantly male cohorts, resulting in opioid dosing regimens that are suboptimal or unsafe for female patients at equivalent pain levels. 4. Psychiatric medications: SSRIs and other psychiatric medications show different efficacy and side effect profiles in women vs.

men, yet placebo-controlled trials often had 60-70% male enrollment despite psychiatric conditions being diagnosed more frequently in women.

The methodological problem: The "perceived complexity" of female subjects referred primarily to hormonal cycle variability — something entirely resolvable through study design (controlling for cycle phase, larger sample sizes, stratified analysis). Instead, researchers chose to simply exclude women, introducing a different kind of complexity: systematic bias in the resulting evidence.

Policy response and ongoing reform:

The NIH has required sex-disaggregated data reporting in grant applications since 2016, and Nature and Science have adopted editorial policies requiring sex/gender reporting in animal and human studies. However, compliance remains incomplete — major journals report that ~30-40% of published animal studies still do not report subject sex.

The research highlights that the shift toward sex-disaggregated medicine is not primarily a problem of data or funding — it is a problem of research culture and institutional incentive structures that historically rewarded simplicity (homogeneous cohorts) over representativeness (diverse cohorts reflecting the eventual treatment population).

Implications for precision medicine: If precision medicine is to deliver on its promise of matching treatments to individual characteristics, sex cannot be treated as noise to be filtered out — it must be treated as a fundamental biological variable that shapes treatment response.

The economic angle: Sex-specific suboptimal dosing results in higher rates of adverse events, treatment failures, and healthcare costs when drugs developed in male-biased trials are scaled to diverse populations. Correcting the research bias has quantifiable cost-savings implications.